DiaMedica's DM-204 for Type 2 Diabetes Significantly Lowers Blood Glucose, Blood Pressure and Cholesterol Levels
December 01 2011 - 8:52AM
Marketwired
DiaMedica Inc. (TSX VENTURE:DMA) is pleased to announce the
presentation of new compelling Type 2 diabetes data from studies of
DM-204 at the Windhover Therapeutic Area Partnership Conference in
Boston, MA, USA.
In an independently conducted study, chronic administration of
DM-204 prevented disease progression within an in vivo Type 2
diabetes model. Treatment with DM-204 resulted in statistically
significant lower mean differences compared to untreated animals
after 21 days for the following parameters:
-- 2.6% (p=0.0103) lower HbA1c levels at day 21
-- 70% (p=0.0058) lower difference in fasting blood glucose levels
-- 25 mm/Hg (p=0.0004) lower difference in systolic blood pressure levels
-- greater than 20% (p=0.0156) improvement in total cholesterol levels
Managing each of these parameters, HbA1c, blood glucose, blood
pressure and cholesterol, is important in the treatment of patients
suffering from Type 2 diabetes. Reduction in HbA1c is the critical
endpoint measurement in receiving regulatory approval for a Type 2
diabetes medication. Additionally, approximately 70% of Type 2
diabetics are prescribed antihypertensive medication(s) to control
blood pressure and prevent heart disease and stroke. The
antihypertensive and cholesterol lowering ability of DM-204 may
significantly reduce the need for such medication(s) and
furthermore protect Type 2 diabetics from heart disease and stroke
complications. Administration of DM-204 was well-tolerated and
outperformed marketed Type 2 diabetes drugs sitagliptin (Januvia®)
and exenatide (Byetta®).
"These results are very encouraging and provide a strong
foundation with which to move DM-204 forward," said Dr. John
Amatruda, DiaMedica's Scientific Advisory Board member and former
Senior Vice President and Franchise Head for Diabetes and Obesity
at Merck Research Laboratories.
"DM-204 has the opportunity to fundamentally change the
treatment regimen for Type 2 diabetes patients with hypertension
and high cholesterol. DM-204 could potentially become the single
long-acting treatment by virtue of being a monoclonal antibody
therapy"," stated Dr. Mark Williams, Vice President, of Research at
DiaMedica. "The chronic in vivo model data shows DM-204's ability
to prevent disease progression of Type 2 diabetes and increased
blood pressure."
Summary results will be presented at the 2011 Windhover's
Therapeutic Area Partnership Conference at 3pm December 1st, 2011
at the Westin Copley Place, Boston, MA with the full results to be
published and presented in 2012.
About DiaMedica
DiaMedica is a biopharmaceutical company that has developed
novel therapeutic compounds aimed to improve the lives of patients
with diabetes and other major, medically-unmet diseases.
DiaMedica's lead compound, DM-199, represents a novel approach to
treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting
the autoimmune attack on beta cells; 2) proliferating insulin
producing beta cells; and 3) improving glucose control.
Treatment with DiaMedica's monoclonal antibody, DM-204, has
demonstrated significant improvement in glucose control, blood
pressure and cholesterol levels in in vivo models of Type 2
diabetes.
The company is listed on the TSX Venture Exchange under the
trading symbol 'DMA'.
Caution Regarding Forward-Looking Information
The statements made in this press release that are not
historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be
considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions
made by and information currently available to management. When
used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements.
You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as
contained in the Company's filings with Canadian securities
regulatory authorities. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company
undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events.
Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
Contacts: DiaMedica Inc. Rick Pauls President & CEO
204.477.7590 204.453.3745 (FAX)rpauls@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024